Manila Times Business
Paratus Sciences Presents Preclinical and Translational Data on PS-1001, a First-in-Class Pan-Inflammasome Inhibitor, at FOCIS 2026
- First-in-human trial of PS-1001 planned to initiate in 2027 - BOSTON and SINGAPORE, June 11, 2026 (GLOBE NEWSWIRE) -- Paratus Sciences ("Paratus”), a global biotechnology company decoding evolution to develop first-in-class medicines for serious diseases, today presented new preclinical and translational data on its lead therapeutic candidate, PS-1001, at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, taking place June 9-12, 2026, in San Francisco, CA. The data indicat
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Ambros Therapeutics Appoints Cris Calsada as Chief Financial Officer and Claire Padgett, Ph.D., as SVP of Clinical Operations and Program Management
2h ago
Manganese X Energy to Present at the June 16 Energy & Precious Metals Virtual Investor Summit
2h ago
Energy & Precious Metals Virtual Investor Summit Agenda Announced for June 16th
2h ago
WatchMatic Highlights Market Trends Influencing Luxury Watch Investment Strategies
2h ago